Days after the state’s primary, California voters are in a familiar position -- waiting to find out which candidates will go ...
Quick action was vital after surprise attack When Methow Valley 8-year-old Tristan Kokes headed downstairs to play with Legos ...
A remand prisoner with intellectual disability, Resh Babu, died in hospital after collapsing in Viyyur Sub Jail. His family ...
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), ...
Myelofibrosis is both a hematologic cancer and aggressive inflammatory disease driven by aberrant proliferation of myeloid ...
Iza-bren is a potentially first-in-class bispecific ADC designed to target both EGFR and HER3. It features high affinity for ...
For income investors hunting yield in a choppy rate environment, business development companies (BDCs) trading under $30 ...
The American Red Cross reports a sharp drop in blood donations as the nation enters the critical summer trauma season.
Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up to $1B U.S. peak sales potential.
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader ...
Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired ...
A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results